Fertility startup Myma Medical has secured an additional £145K from innovation management consultancy LYVA Labs. bringing LYVA Labs’ total support for the UK-based startup to £779K, including grant leverage.
Founded as a spinout from the University of Birmingham, Myma Medical is advancing fertility treatments with its patented autoICSI (Intracytoplasmic Sperm Injection) system. The next-gen technology aims to minimize inconsistencies that often occur in manual egg manipulation and sperm injection processes, thereby substantially improving IVF success rates.
Myma Medical’s technology employs an AI-based high-definition vision camera system that uses algorithms and artificial intelligence for precise detection and positioning of eggs prior to injection. Moreover, it utilizes AI algorithms to assess sperm morphology and motility against clinical benchmarks to ensure the selection of the most viable sperm for injection.
Yash Khandhia, CEO of Myma Medical, commented: “The investment from LYVA Labs will allow the company to complete the development of autoICSI and associated AI-based high-definition vision camera system in record time, to get the system ready for full clinical trial and to present it for regulatory approval before commercialisation.”
LYVA Labs first invested £105K in Myma Medical in 2022, which enabled the startup to secure an Innovate UK SMART grant of £389K. With additional support, the company also leveraged a £140K Innovate UK Future Economy Investor Partnerships grant.
Lorna Green, CEO of LYVA Labs, shared: “We’re delighted to provide further investment and business support to Myma Medical. They are developing a technology that can bring about a step change in the success of fertility treatments and deliver real results for families across the UK.”
With this new injection of funds, Myma Medical plans to bring its fertility treatment technology to the market.
